Alumis (ALMS) vs Alto Neuroscience (ANRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed Alumis (ALMS) over the past year, gaining 296.0% versus a gain of 50.1%. Alto Neuroscience is the larger company by market cap ($913.2 million vs $867.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | ANRO |
|---|---|---|
| Share price | $6.70 | $23.27 |
| Market cap | $867.22M | $913.16M |
| 1-day change | -1.03% | -1.06% |
| YTD return | -30.64% | +32.13% |
| 1-year return | +50.11% | +295.96% |
| EPS (TTM) | $-3.86 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $37.48 |
| 52-week low | $4.28 | $5.23 |
| Distance from 52-week high | -78.63% | -37.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +379.55% | +64.93% |
| Average volume | 2.43M | 540.09K |
| Shares outstanding | 129.44M | 39.24M |
| Employees | 237 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed ALMS by 245.8 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
ALMS vs ANRO FAQ
Which is bigger, Alumis or Alto Neuroscience?
Alto Neuroscience (ANRO) is larger, with a market capitalization of $913.16M compared with $867.22M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or ANRO?
ANRO returned +295.96% over the past 12 months, compared with +50.11% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Alto Neuroscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.